• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » NeuroWave Systems readies first product without a dime of investment

NeuroWave Systems readies first product without a dime of investment

April 22, 2010 By MedCity News

MedCity News logo

By Mary Vanac

Cleveland Medical Devices spin-off company NeuroWave Systems Inc. is poised to introduce its first commercial product — the NeuroSense Monitor — without taking a single investor dollar.

NeuroSense is a monitor that measures, analyzes and tracks the brain function of sedated or anesthetized patients. So far, NeuroWave and its former parent CleveMed have used federal grants and contracts, and at least one state grant, to develop NeuroSense and other brain monitoring technologies, president and co-founder Tatjana Zikov said.

NeuroWave was spun off in 2008 by CleveMed, a developer of biomedical signal processing and instrumentation devices. NeuroWave moved to its own offices in Cleveland Heights about a year ago. Last week, CleveMed formalized the spin-off by transferring licenses for anesthesia-monitoring and seizure-detection technologies to NeuroWave, which employs 10 full-time workers and six part-time consultants.

“This spin-off is the realization of our 15 years of dedication to research in intelligent and automated brain monitoring,” said Mo Modarres, vice chairman and co-founder of NeuroWave, in a CleveMed press release about the license transfers. “We are now fully self-sustaining and profitable, while our new products will allow for substantial growth.”

The market for brain wave-monitoring devices used during anesthesia is estimated at more than $1 billion a year and growing, according to CleveMed. The market is dominated by Aspect Medical Systems Inc. of Norwood, Mass., according to Neurotech Business Report. Covidien plc acquired Aspect in November 2009 for $210 million.

Aspect uses bispectral index technology to measure and analyze brain waves to gauge the depth of consciousness during anesthesia. NeuroWave uses a technology known as “wavelet-based anesthetic value,” which it claims outperforms bispectral index technology, according to Neurotech Business Report. Chesterfield, Mo.-based engineering firm Everest Biomedical Instruments markets a system that uses yet another technology to assess consciousness, NBR said.

“Brain function monitors are not, as of yet, standard of care,” said Zikov, co-inventor of the NeuroSense technology. “The benefits of these monitors have been widely publicized. We would be on a good path if these, indeed, become standard of care in years to come.”

The NeuroWave system acquires and displays electroencephalogram signals from both sides of the front part of the brain. The system quantifies brain activity in patients undergoing general anesthesia or sedation. It also qualifies this information by providing real-time feedback on both cerebral hemispheres. In this way, NeuroSense could improve patient safety and outcomes during anesthesia.

In 2003, CleveMed licensed the intellectual property behind NeuroSense from the University of British Columbia and BioNova Technologies Inc., where it was invented and developed, respectively, by Zikov and fellow graduate student Stephane Bibian. Zikov is co-founder of BioNova, which, like the university, is located in British Columbia and was formed to help transfer promising technology to industry from academia, she said.

“NeuroWave is committed to improving patient outcome and quality of life by making brain monitoring cost-effective and accessible through innovative signal processing of brain waves,” Zikov said. “The NeuroSense is the first milestone towards that goal.”

So far, NeuroWave has sustained itself with grants and contracts from the National Institutes of Health and the U.S. Dept. of Defense, Zikov said. She couldn’t put her finger on the amount of grant and contract money NeuroWave has received, because the money came through CleveMed during the company’s formative years.

A search of NIH awards in Ohio revealed NeuroWave received a $1.4 million grant in 2009 and a $1.1 million grant in 2008. The company also benefited from a $174,791 Ohio Third Frontier commercialization grant in 2004.

“Our added value is in bringing the benefits of intelligent signal processing to extract clinical information from biological signals,” Zikov said.

The NeuroSense system is being tested in Europe, where it also is awaiting regulatory market approval. NeuroWave has applied to the Food & Drug Administration for clearance in the U.S. However, it’s likely that European approval will come first, Zikov said.

Meanwhile, NeuroWave is developing NeuroMedic and NeuroFast seizure detection devices for emergency room and pre-hospital patients in both civilian and military settings. NeuroWave is the only company selected by both the NIH and the Defense Dept. to develop seizure detection devices to monitor patients exposed to chemical warfare agents, CleveMed said.

Zikov was not ready to comment on whether her company would become a developer of neuro-monitoring technologies for other companies to commercialize, or one that commercializes those technologies, too. Instead, she said, “We are definitely focusing on efforts to have successful commercialization of our first product, and have a couple of promising technologies in the pipeline.”

Filed Under: Business/Financial News, Neurological, News Well Tagged With: Anesthesia, Aspect Medical Systems Inc., Covidien, NeuroWave Systems Inc.

In case you missed it

  • iRhythm stays silent on federal grand jury subpoenas
  • Texas power grid struggles a year after cold stopped semiconductor plants
  • The road to a robot: Medtronic’s development process for Hugo RAS system
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
  • Zimmer Biomet appoints new chief accounting officer
  • Cook Medical makes next-gen in vitro fertilization incubator available in U.S., Canada
  • Boston Scientific co-founder Peter Nicholas is dead at 80
  • How Boston Scientific uses clinical feedback to advance innovation
  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
  • Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns
  • Abbott partners with Women as One to help more underrepresented clinicians lead trials
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring

RSS From Medical Design & Outsourcing

  • iRhythm stays silent on federal grand jury subpoenas
    More than one year after receiving the first of two federal grand jury subpoenas seeking information about its products and communications with the FDA, iRhythm Technologies has said little publicly about the matter. It would have been easy to miss the San Francisco-based cardiac monitor maker’s initial disclosure last summer. iRhythm (Nasdaq:IRTC) was without a… […]
  • How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
    A lot of talk around Dexcom (Nasdaq:DXCM) in the last couple of years has centered around its next-generation G7 continuous glucose monitor. The latest iteration of the company’s CGM platform has already garnered CE mark this year and awaits FDA approval, with some expectations for that to come after the American Diabetes Association’s Scientific Sessions next month. The company also presented… […]
  • Texas power grid struggles in heat one year after record cold stopped semiconductor plants
    A heat wave in Texas took at least six power plants offline Friday with high temperatures forecasted to blaze throughout this week. A record cold snap in February 2021 took NXP Semiconductors and Samsung chip fabrication facilities offline for weeks, contributing to a global semicondcutor shortage that is still throttling medical device production. There’s no… […]
  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS